Form 13-F position report

ADICET BIO INC

Reported by STATE STREET CORPORATION

ACET CUSIP 007002108 Manager CIK 0000093751

Reported 244,821 shares, down 695,413 (74.0%) from the prior quarter.

Reported value -86.6%; share count -74.0% vs. the prior quarter.

Reduced
% of reported 13F value < 0.01% This manager · Q2 2024
Shares 244,821 Quarter-end amount reported
Reported value $296,233 Fair value at quarter end
Consecutive quarters held 16 Through Q2 2024

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 5727000
2022-03-31 7923000
2022-06-30 6947000
2022-09-30 27847000
2022-12-31 20424199
2023-03-31 3251272
2023-06-30 1369947
2023-09-30 867940
2023-12-31 1210626
2024-03-31 2209550
2024-06-30 296233
2024-09-30 330798
2024-12-31 237538
2025-03-31 186425
2025-06-30 150622
2025-09-30 197840
2025-12-31 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

17 quarters
Quarterly reported position history for ADICET BIO INC held by STATE STREET CORPORATION.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q4 2025 Reduced 0 -244,186 (-100.0%) 0 $0 2026-02-13
Q3 2025 Reduced 244,186 -2,735 (-1.1%) < 0.01% $197,840 2025-11-14
Q2 2025 Unchanged 246,921 0 (0.0%) < 0.01% $150,622 2025-08-14
Q1 2025 Unchanged 246,921 0 (0.0%) < 0.01% $186,425 2025-05-15
Q4 2024 Added 246,921 +17,200 (7.5%) < 0.01% $237,538 2025-02-14
Q3 2024 Reduced 229,721 -15,100 (-6.2%) < 0.01% $330,798 2024-11-14
Q2 2024 Reduced 244,821 -695,413 (-74.0%) < 0.01% $296,233 2024-08-14
Q1 2024 Added 940,234 +299,691 (46.8%) < 0.01% $2,209,550 2024-05-15
Q4 2023 Added 640,543 +7,010 (1.1%) < 0.01% $1,210,626 2024-02-14
Q3 2023 Added 633,533 +69,769 (12.4%) < 0.01% $867,940 2023-11-14
Q2 2023 Reduced 563,764 -693 (-0.1%) < 0.01% $1,369,947 2023-08-14
Q1 2023 Reduced 564,457 -1,720,129 (-75.3%) < 0.01% $3,251,272 2023-05-15
Q4 2022 Added 2,284,586 +326,321 (16.7%) < 0.01% $20,424,199 2023-02-14
Q3 2022 Added 1,958,265 +1,482,409 (311.5%) < 0.01% $27,847,000 2022-11-15
Q2 2022 Added 475,856 +79,088 (19.9%) < 0.01% $6,947,000 2022-08-15
Q1 2022 Added 396,768 +69,327 (21.2%) < 0.01% $7,923,000 2022-05-16
Q4 2021 Added 327,441 +31,194 (10.5%) < 0.01% $5,727,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

117 managers reported ADICET BIO INC for Q2 2024.

Managers reporting ADICET BIO INC in Q2 2024.
Manager Activity Shares Change % of reported 13F Reported value Tenure
ORBIMED ADVISORS LLC Unchanged 11,447,140 0 0.28% $13,851,039 16 qtrs
TANG CAPITAL MANAGEMENT LLC Added 8,216,960 +1,809,560 1.01% $9,942,522 7 qtrs
RA CAPITAL MANAGEMENT L P Unchanged 7,541,000 0 0.12% $9,124,610 2 qtrs
The Goldman Sachs Group Inc Added 4,283,372 +277,785 < 0.01% $5,182,880 15 qtrs
MILLENNIUM MANAGEMENT LLC Reduced 3,621,670 -484,500 < 0.01% $4,382,221 9 qtrs
VANGUARD GROUP INC Reduced 3,099,956 -26,622 < 0.01% $3,750,947 16 qtrs
Carlyle Group Inc Unchanged 2,948,718 0 0.34% $3,597,436 6 qtrs
Aquilo Capital Management LLC New 2,531,194 +2,531,194 2.95% $3,062,745 1 qtr
RENAISSANCE TECHNOLOGIES LLC Added 1,512,600 +463,600 < 0.01% $1,830,246 9 qtrs
Blackstone Inc Unchanged 1,236,453 0 < 0.01% $1,496,108 2 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2024
Filed
August 14, 2024
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
244,821
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.